After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers scientists' expertise to find viable target antigens for CAR T cell ...

T cells offer several advantages for solid tumor immunotherapy, including innate tumor recognition, human leukocyte ...

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and ...

Target selection leverages DLL3’s high tumor-surface expression in SCLC/LCNEC and limited normal-tissue expression, while dnTGFBR2 “armoring” aims to blunt TGF-β–mediated T-cell suppression. Dose ...

Malcolm Brenner, an internationally recognized physician‑scientist renowned for his leadership in cell and gene therapy, has been tapped to lead the newly formed Houston Methodist Center for Cell and ...

Automation, decentralized manufacturing, and supportive regulations are helping to surmount technical difficulties in cell and gene therapy manufacturing.